ZVRA Q1 2024 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+7.8% YoY

Gross Profit

$160,0004.7% margin

Operating Income

-$20M-598.1% margin

Net Income

-$17M-485.3% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-74.1%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$151M

Total Liabilities

$102M

Stockholders' Equity

$49M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+7.8%
Gross Profit	$160,000	$3M	-94.8%
Operating Income	-$20M	-$13M	-59.7%
Net Income	-$17M	-$13M	-25.8%

Revenue Segments

License

$1M100%